Member Info for CHELSEA7

Great post Ivy.

Afternoon............................................

http://www.hardmanandco.com/docs/default-source/mohtnly-newsletters/hardman-co-monthly---july-2018.pdf

Morning nomlungu, I don"t think that is pressure selling at all. Good to see some old marketing tools still used. It certainly allows the company to gauge the cost to marketing and the consumer has an opportunity to pay a discounted price.

Have a good day.

By as ever goosed on ADVFN.

https://www.medscape.com/viewarticle/898205?src=WNL_confwrap_180628_MSCPEDIT&uac=290144MJ&impID=1670737&faf=1#vp_3?src=soc_tw_share

From last night 16.31 at 12.55

Good news, probably just a wives tail but my parents spoke of certain diseases missing a generation in families. All my grandparents died from cancer, missed my parents and three out of four, children of my mother and sister have had cancer these last few years. Wild, have you heard anything similar??

Re your post yesterday, yes another buying opportunity presenting, not in the market for more myself, i really have enough. Just hoping we don"t see further falls, in the absence of any serious buying.

Best regards Wild, happy hunting. ATB

LOL.......................................

gooosed29 Jun '18 - 09:07 - 16533 of 16536
0 0 0
Last day of H1 2018 - back in January it was reasonable to expect news in the first half of 2018.

Https://www.youtube.com/watch?v=2PFQ9sLXO_8 from 06:30

Not so reasonable now - hmmmm.

https://endpts.com/how-does-the-first-half-of-2018-measure-up-against-the-last-7-years-for-biotech-ipos/?utm_medium=email&utm_campaign=511%20Fri%2062918%20Industry%20IPOs%20hit%20fever%20pitch%20nearing%202014%20high%20score%20in%20H1%20FDA%20OKs%20Dermiras%20anti-sweat%20drug&utm_content=511%20Fri%2062918%20Industry%20IPOs%20hit%20fever%20pitch%20nearing%202014%20high%20score%20in%20H1%20FDA%20OKs%20Dermiras%20anti-sweat%20drug+CID_9dd80d0ca890e25b4d8df7e0d5c8557f&utm_source=ENDPOINTS%20emails&utm_term=How%20does%20the%20first%20half%20of%202018%20measure%20up%20against%20the%20last%207%20years%20for%20biotech%20IPOs

12.50/13

12.5/12.8

Wins off the bid. 2 v 1

As ONW replied to you..............................

You may think so, I don't.
I'm quite happy with my post thanks, I'm the final arbiter of what I write, not you.
ATB

so this falls under the heading

Expected = promise ...

so what i can say is ....

"you are making stuff up which cannot be reasoned by others"

What a load of rubbish!!!!! For all the reasons you give this should be a buy, for our cash position, we should be a buy, for our realistic chances of winning a huge pay out from CRUK, we should be a buy.......................but instead we softly fall from 15.5 to sub 13p. Didn"t seem much problem updating us for the placing and OO, did it???

I feel very sure that knowing an important timeline is still on schedule, after a few disappointments on the way, we would see far more support sub 13p, onto Monday, yes i do agree we have many irons in the fire, a lot is dependant on Grand Challenge too, for future Moditope trials, hopefully we have found a new bottom. GL All

29/06/2018 10:57 23,527 12.92

And a 10k buy here at 12.90

Well yes it has been promised. IND submission by end H1, Trial commencement by end 2018!!!!

I actually have few doubts we would be too far off those schedules, but that being the case how can you with any credibilitity post against an update on SCIB 1 being due.??? However you wish to twist it.

I agree.. I thought it was a case of Ichor submitting an IND, then us following.. TBH I would be happy to hear that first patients are being recruited for trial as a result of Trial Approval.

We only had two items down for H1 as from memory. So yes no news can be construed as bad news. We have been very understanding and patient as to previous timelines, this is not necessary, it is called communication, something a Public Company should be very good at. Just MO.

RHatton posted something up positive re a reply from the BOD Rre SCIB1 IND. Worth a look.

Now 12.72 from 12.69

BioPharma Dive recently took an in-depth look at the vaccines market. One notable observation—four companies dominate the entire space, GlaxoSmithKline, Merck & Co., Sanofi and Pfizer. “Unlike most drugs,” Jacob Bell wrote, “vaccines are typically meant to prevent disease rather than treat it, and that presents unique challenges in the clinic. They also require large-scale manufacturing capabilities, something that is regularly out of reach for smaller biotechs, in turn compelling them to seek partnerships with the big four.”

And that’s supported by the fact there are about 327 anti-infective vaccines in preclinical testing and 282 more in Phase I through pre-registration, according to Informa. But most smaller biotech companies get to about Phase II and start looking for partnerships with the big four or other larger companies, such as Takeda Pharmaceutical.

"Not a mention of Cancer vaccines"

Very wise words. Just waiting for the clouds to lift, a blue sky has been assured at least. ATB